Bioequivalence of two enteric coated formulations of pantoprazole in healthy volunteers under fasting and fed conditions

• Published in: Arzneimittel-Forschung Vol. 57; no. 6; pp. 309 - 314
• Main Authors: ROSSI DE CAMPOS, Daniel, ROGERIO VIEIRA, Nelson, BURANELLO, Simoni, CRISTINO SILVA, Andréia Rodrigues, RICARDO AMARANTE, Antonio, ABIB, Eduardo, PEDRAZZOLI JUNIOR, José, BERNASCONI, Gilberto, PROENCA BARROS, Fabio Alessandro, MEURER, Eduardo Cesar, MARCLUORETTO, Marco Antonio, CAPOBIANGO COELHO, Edvaldo, APARECIDA CALAFATTI, Silvana, SOMMER, Carolina, MOREIRA COUTO, Jussara
• Format: Journal Article
• Language: English
• Published: Aulendorf Cantor 2007
• Subjects: 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage; 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacokinetics; Anti-Ulcer Agents - administration & dosage; Anti-Ulcer Agents - pharmacokinetics; Area Under Curve; Biological and medical sciences; Chemistry, Pharmaceutical; Cross-Over Studies; Excipients; Fasting - physiology; Humans; Mass Spectrometry; Medical sciences; Pharmacology. Drug treatments; Solubility; Tablets, Enteric-Coated; Therapeutic Equivalency; Bioequivalence; Pantoprazole, bioequivalence, biorelevant dissolution testing; H; Antiulcer agent; K; Antiulceratives; CAS 102625-70-7; Proton pump inhibitor; Antisecretory agent; Formulation; Human; Fasting; Healthy subject; Pantoprazole; Enzyme; Enzyme inhibitor; Medical screening; Enteric coating; Dissolution; Feeding; Benzimidazole derivatives; Dosage form; exchanging ATPase; Hydrolases; Proton pump inhibitors; Pharmacokinetics
• ISSN: 0004-4172
• DOI: 10.1055/s-0031-1296624

To compare the bioavailability of two pantoprazole (CAS 102625-70-7) formulations (40 mg pantoprazole enteric coated tablets) under fasted and fed conditions as well as to evaluate the dissolution profile in biorelevant media.
The subjects received either 40 mg of the reference or of test formulation in fasting (n = 28) and fed (n=70) condition. The studies were conducted according to a single dose and randomized crossover design. Blood samples were collected up to 12 h after drug administration in fasting condition and up to 48 h in fed condition. Plasma concentrations of pantoprazole were determined by LC-MS/MS. Pharmacokinetic parameters were calculated from the observed plasma concentration-time profiles. Bioequivalence between the formulations in fasting and fed condition was assessed considering 90% confidence intervals for the ratio of means for lnCmax and lnAUC(0-t) within 0.8-1.25. Dissolution profiles were evaluated in biorelevant media [Fasting State Simulating Intestinal Fluid (FaSSIF) and Fed State Simulating Intestinal Fluid (FeSSIF)]. The sameness of the dissolution curves was assessed by f2 values between 50 and 100.
Under fasting condition the 90% confidence interval for the ratio of means for the lnCmax, (0.94-1.03) and lnAUC(0-t) (0.89-0.99) was within the guideline range of bioequivalence (0.80-1.25). However, the data for lnCmax (0.51-0.76) and lnAUC(0-t) (0.68-0.90) under fed condition were not within the bioequivalence range. The postprandial study demonstrated a high intra-subject variability and in some subjects pantoprazole could not be detected for up to 24 h, although the dissolution profile of reference and test formulations presented a similar disposition in FaSSIF and FeSSIF as confirmed by the values of f2 higher than 50.
The results demonstrated that the test formulation was bioequivalent to the reference in fasting condition but not in postprandial state. The dissolution profile in FaSSIF indicates that this biorelevant medium was more adequate to discriminate the in vivo disposition of pantoprazole than FeSSIF. Furthermore, the fed condition study had shown a pronounced influence of food in the absorption of pantoprazole after single oral dose administration.